Two Sigma Investments
AST

Two Sigma Investments’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Two Sigma Investments’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,371
Closed -$62K – 3611
2016
Q4 		$62K Buy
+13,371
New +$55.2K ﹤0.01% 3003

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Investments's AST Position: Q1 2017 in Review

Two Sigma Investments sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2017, closing a stake of 13,371 shares — an estimated $62K sold.

Two Sigma Investments first reported a position in AST in Q4 2016 and held it in 1 quarter. The position peaked at $62K in Q4 2016. 66 funds tracked by Wall St. Rank hold AST as of Q1 2017.

  • Two Sigma Investments reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2017 after selling out during the quarter.
  • Two Sigma Investments sold 13,371 Asterias Biotherapeutics Inc. Series A shares in Q1 2017, an estimated $62K.
  • Two Sigma Investments first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2016 and held it in 1 quarter.
  • Two Sigma Investments's Asterias Biotherapeutics Inc. Series A position peaked at $62K in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2017.

Based on Two Sigma Investments's 13F filing for Q1 2017, filed 15 May 2017.